Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: Case report

A. Suwa, Michito Hirakata, Yuko Kaneko, S. Sato, Y. Suzuki, M. Kuwana

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We describe a patient who presented with polymyositis with anti-Jo-1 antibodies at 18 years after the onset of rheumatoid arthritis and was successfully treated with the immunosuppressive drug mizoribine at the time of exacerbation. She had developed diabetes mellitus, cerebral infarction, and myocardial infarction after high-dose steroid therapy was initiated. Therefore, an immunosuppressant was preferred as the second-line agent. Treatment with 150 mg/day of mizoribine and 8 mg/day of prednisolone resulted in eventual normalization of muscle enzyme levels. Mizoribine is a purine antimetabolite that inhibits T cell activation/proliferation and B cell proliferation. The potential efficacy of mizoribine for polymyositis was suggested by this case.

Original languageEnglish
Pages (from-to)227-229
Number of pages3
JournalClinical Rheumatology
Volume28
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Polymyositis
Immunosuppressive Agents
Cell Proliferation
Antimetabolites
Cerebral Infarction
Therapeutics
Prednisolone
Rheumatoid Arthritis
Diabetes Mellitus
B-Lymphocytes
Steroids
Myocardial Infarction
T-Lymphocytes
Muscles
bredinin
Enzymes
Pharmaceutical Preparations

Keywords

  • Glucocorticoid
  • Immunosuppression
  • Mizoribine
  • Polymyositis
  • Therapy

ASJC Scopus subject areas

  • Rheumatology

Cite this

Successful treatment of refractory polymyositis with the immunosuppressant mizoribine : Case report. / Suwa, A.; Hirakata, Michito; Kaneko, Yuko; Sato, S.; Suzuki, Y.; Kuwana, M.

In: Clinical Rheumatology, Vol. 28, No. 2, 2009, p. 227-229.

Research output: Contribution to journalArticle

@article{cd9ebba4232a4eaa96d77c635f35b770,
title = "Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: Case report",
abstract = "We describe a patient who presented with polymyositis with anti-Jo-1 antibodies at 18 years after the onset of rheumatoid arthritis and was successfully treated with the immunosuppressive drug mizoribine at the time of exacerbation. She had developed diabetes mellitus, cerebral infarction, and myocardial infarction after high-dose steroid therapy was initiated. Therefore, an immunosuppressant was preferred as the second-line agent. Treatment with 150 mg/day of mizoribine and 8 mg/day of prednisolone resulted in eventual normalization of muscle enzyme levels. Mizoribine is a purine antimetabolite that inhibits T cell activation/proliferation and B cell proliferation. The potential efficacy of mizoribine for polymyositis was suggested by this case.",
keywords = "Glucocorticoid, Immunosuppression, Mizoribine, Polymyositis, Therapy",
author = "A. Suwa and Michito Hirakata and Yuko Kaneko and S. Sato and Y. Suzuki and M. Kuwana",
year = "2009",
doi = "10.1007/s10067-008-1050-6",
language = "English",
volume = "28",
pages = "227--229",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - Successful treatment of refractory polymyositis with the immunosuppressant mizoribine

T2 - Case report

AU - Suwa, A.

AU - Hirakata, Michito

AU - Kaneko, Yuko

AU - Sato, S.

AU - Suzuki, Y.

AU - Kuwana, M.

PY - 2009

Y1 - 2009

N2 - We describe a patient who presented with polymyositis with anti-Jo-1 antibodies at 18 years after the onset of rheumatoid arthritis and was successfully treated with the immunosuppressive drug mizoribine at the time of exacerbation. She had developed diabetes mellitus, cerebral infarction, and myocardial infarction after high-dose steroid therapy was initiated. Therefore, an immunosuppressant was preferred as the second-line agent. Treatment with 150 mg/day of mizoribine and 8 mg/day of prednisolone resulted in eventual normalization of muscle enzyme levels. Mizoribine is a purine antimetabolite that inhibits T cell activation/proliferation and B cell proliferation. The potential efficacy of mizoribine for polymyositis was suggested by this case.

AB - We describe a patient who presented with polymyositis with anti-Jo-1 antibodies at 18 years after the onset of rheumatoid arthritis and was successfully treated with the immunosuppressive drug mizoribine at the time of exacerbation. She had developed diabetes mellitus, cerebral infarction, and myocardial infarction after high-dose steroid therapy was initiated. Therefore, an immunosuppressant was preferred as the second-line agent. Treatment with 150 mg/day of mizoribine and 8 mg/day of prednisolone resulted in eventual normalization of muscle enzyme levels. Mizoribine is a purine antimetabolite that inhibits T cell activation/proliferation and B cell proliferation. The potential efficacy of mizoribine for polymyositis was suggested by this case.

KW - Glucocorticoid

KW - Immunosuppression

KW - Mizoribine

KW - Polymyositis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=58149185084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149185084&partnerID=8YFLogxK

U2 - 10.1007/s10067-008-1050-6

DO - 10.1007/s10067-008-1050-6

M3 - Article

C2 - 19082529

AN - SCOPUS:58149185084

VL - 28

SP - 227

EP - 229

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 2

ER -